Drug
Satralizumab
Satralizumab: highest development phase Phase 3, developed by Roche. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Satralizumab NCT02073279 | Phase 3 | Neuromyelitis Optica (NMO) |
| Satralizumab NCT05503264 | Phase 3 | NMDAR Autoimmune Encephalitis |
| Satralizumab NCT05271409 | Phase 3 | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) |
| Satralizumab NCT04963270 | Phase 3 | Generalized Myasthenia Gravis |
Latest
No recent events.
Follow Satralizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.